Curaleaf to Open Six New Dispensaries

Curaleaf will be opening a cultivation and processing facility and up to six dispensaries, under the Commonwealth's medical marijuana research program.

Curaleaf Holdings, Inc, a leading vertically integrated cannabis operator in the United States, has been approved as a Clinical Registrant in Pennsylvania by the Commonwealth's Department of Health, Office of Medical Marijuana.

Under this designation, the Company will be permitted to open a cultivation and processing facility and up to six dispensaries, under the Commonwealth's medical marijuana research program. 

As a Clinical Registrant, Curaleaf will support research initiatives into the potential medical benefits of cannabis by providing medical cannabis, expertise and distribution to patients participating in studies.

In announcing the awards of the clinical registrant licenses, Dr. Rachel Levine of the Pennsylvania Department of Health remarked; "Pennsylvania remains on the forefront for clinical research on medical marijuana. This research is essential to providing physicians with more evidence-based research to make clinical decisions for their patients."

It is the cornerstone of our program and the key to our clinically based, patient-focused program for those suffering with cancer, PTSD and other serious medical conditions."

Joe Lusardi, Chief Executive Officer of Curaleaf, said, "We thank the Pennsylvania Department of Health for approving Curaleaf to participate in this vital research program. "

"The Pennsylvania State Legislature mandated research as a component of its medical cannabis program, setting it apart from the rest of the nation. Curaleaf has always been focused on high-quality cannabis products, as well as superior patient care and education. We look forward to contributing to medical research that will ultimately benefit not only the residents of the Commonwealth, but the entire country."

To learn more about Curaleaf Holdings visit their Company HQ here

Disclaimer: Past performance is not an indicator of future performance.


This could be one of the best investing opportunities of 2020

Legislative changes are blowing through the US, and with it, an ever-increasing number of states legalising cannabis for recreational use.

With the success seen in Illinois, which legalised for adult-use on January 1 and saw products moving off the shelf at an unprecedented rate, this company is primed to take advantage of the booming US recreational market.

They have secured partnerships with the biggest cannabis companies in the US, and their portfolio is second to none.

And with the sector-wide pullback of 2019, this company is now at a bargain-basement price.

Subscribe Now
& Keep Up to Date

Get the latest pot stock recommendations, cannabis news
and industry updates straight to your inbox!

Niki Mohazeb
Niki Mohazeb

Niki is a Sydney based writer, with a passion for promoting the health benefits of medicinal cannabis. Niki also enjoys researching and writing about the future of cannabis along with the many other benefits that the plant provides, such as the diverse utilities of hemp.

Leave a Reply

Your email address will not be published. Required fields are marked *